Sotiropoulos G C, Hilgard P, Antoch G, Nowak K M, Ertl J, Fouzas I, Molmenti E P, Sgourakis G, Beckebaum S, Paul A, Broelsch C E, Lang H
Department of General, Visceral, and Transplantation Surgery, University Hospital Essen, Essen, Germany.
Transplant Proc. 2008 Dec;40(10):3804-5. doi: 10.1016/j.transproceed.2008.09.036.
Yttrium-90 microspheres constitute one of the most recent treatment options for hepatocellular carcinoma (HCC) in the setting of cirrhosis. As such, their spectrum of indication is not yet fully established. Herein, we have reported the case of a patient with HCC beyond the listing criteria for liver transplantation (OLT) who was treated preoperatively with selective transarterial chemoembolization and yttrium-90 microspheres. He was subsequently transplanted with a liver from an 81-year-old donor allocated through Eurotransplant as a "rescue offer." The posttransplant course was uneventful. Pathologic examination revealed a multifocal, well-differentiated pT2 tumor with no vascular invasion. The patient is currently alive and in good condition at 14 months posttransplant, with no evidence of tumor recurrence by a current computed tomography scan. This report provided encouraging information on the potential of yttrium-90 microspheres as a bridging option before OLT for multifocal HCC.
钇-90微球是肝硬化背景下肝细胞癌(HCC)最新的治疗选择之一。因此,其适应证范围尚未完全明确。在此,我们报告了1例HCC患者,其病情超出了肝移植(OLT)的列入标准,术前接受了选择性经动脉化疗栓塞和钇-90微球治疗。随后,他接受了通过欧洲移植组织分配的1名81岁供体的肝脏移植,作为“救援供肝”。移植后过程顺利。病理检查显示为多灶性、高分化的pT2肿瘤,无血管侵犯。该患者目前在移植后14个月仍存活且状况良好,目前的计算机断层扫描未显示肿瘤复发迹象。本报告提供了关于钇-90微球作为多灶性HCC患者OLT前桥接选择潜力的鼓舞人心的信息。